JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Pamiparib maleate, the maleate salt of pamiparib (also known as BGB-290), is a novel, potent and selective inhibitor of PARP1 and PARP2 with IC50 values of 0.83 and 0.11 nM, respectively in enzymatic assays. Pamiparib diaplays high selectivity over other PARP enzymes. It has good DMPK (Drug metabolism and pharmacokinetic) profiles. Pamiparib selectively binds to PARP and prevents PARP-mediated repair of single-strand DNA breaks via the base-excision repair (BER) pathway which enhances the accumulation of DNA strand breaks, promotes genomic instability, and eventually leads to apoptosis. Pamiparib can potentiate the cytotoxicity of DNA-damaging agents and reverse the chemo- and radioresistance of tumor cells. Pamiparib is currently under clinical investigation and has the potential to be used for the treatment of various cancers including the solid tumor.
References: AACR 106th Annual Meeting 2015; Supplement/1651; AACR 106th Annual Meeting 2015_Supplement/1653; WO 2013097225 A1.
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Recommend by mail
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!